Sign In
Buy ANIX
$2.52
-0.0300 (-1.18%)
At Close: Jun 03, 2026
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
09:00am, Wednesday, 12'th Nov 2025
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE, Calif. , Nov. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
10:30am, Monday, 10'th Nov 2025
SAN JOSE, Calif. , Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today a
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 05'th Nov 2025
Here is how ANIXA BIOSCIENCES INC (ANIX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
08:55am, Wednesday, 05'th Nov 2025
Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial SAN JOSE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
08:45am, Thursday, 23'rd Oct 2025
SAN JOSE, Calif. , Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
08:25am, Monday, 20'th Oct 2025
Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into 2040 SAN JOSE, Calif. , Oct. 20,
Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice
01:01pm, Friday, 17'th Oct 2025
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
08:30am, Tuesday, 07'th Oct 2025
Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine Comprehensive Immune Response and Safety Data to Be Presented at the San Antonio Breast Cancer Symposiu
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Di
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
06:45pm, Tuesday, 09'th Sep 2025
Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies.
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ --
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
08:54am, Tuesday, 02'nd Sep 2025
SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
09:13am, Monday, 25'th Aug 2025
SAN JOSE, Calif. , Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today a
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will pr
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
09:00am, Monday, 18'th Aug 2025
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:
